-
Journal of Gynecologic Oncology Jan 2015In this study we utilized the Surveillance, Epidemiology and End-Results (SEER) registry to identify risk factors for lymphatic spread and determine the incidence of...
OBJECTIVE
In this study we utilized the Surveillance, Epidemiology and End-Results (SEER) registry to identify risk factors for lymphatic spread and determine the incidence of pelvic and para-aortic lymph node metastases in patients with uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) who underwent complete surgical staging and lymph node dissection.
METHODS
Nine hundred seventy-two eligible patients diagnosed between 1998 to 2009 with International Federation of Gynecology and Obstetrics (FIGO) 1988 stage IA-IVA UPSC (n=685) or UCCC (n=287) were identified for analysis. Binomial logistic regression was used to determine risk factors for lymph node metastasis, with the incidence of pelvic and para-aortic lymph node metastases reported for each FIGO primary tumor stage. The Cox proportional hazards regression model was used to determine factors associated with overall survival.
RESULTS
FIGO primary tumor stage was the only independent risk factor for lymph node metastasis (p<0.01). The incidence of pelvis-only and para-aortic lymph node involvement according to the FIGO primary tumor stage were as follows: IA (2.3%/3.8%), IB (7.5%/5.2%), IC (22.5%/16.9%), IIA (20.8%/13.2%), IIB (25.7%/14.9%), and III/IV (25.7%/24.3%). Prognostic factors for overall survival included lymph node involvement (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.09 to 1.85; p<0.01), patient age >60 years (HR, 1.70; 95% CI, 1.21 to 2.41; p<0.01), and advanced FIGO primary tumor stage (p<0.01). Tumor grade, histologic subtype, and patient race did not predict for either lymph node metastasis or overall survival.
CONCLUSION
There is a high incidence of both pelvic and para-aortic lymph node metastases for FIGO stages IC and above uterine papillary serous and clear cell carcinomas, suggesting a potential role for lymph node-directed therapy for these patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Incidence; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Staging; Pelvis; SEER Program; United States; Uterine Neoplasms
PubMed: 25310855
DOI: 10.3802/jgo.2015.26.1.19 -
International Journal of Clinical and... 2020To explore the clinicopathologic features and differential diagnosis of breast primary mucinous cystadenocarcinoma (MCA).
OBJECTIVE
To explore the clinicopathologic features and differential diagnosis of breast primary mucinous cystadenocarcinoma (MCA).
METHODS
Pathological characteristics and immunophenotype of one case of MCA were analyzed. Literature was reviewed.
RESULTS
Grossly, the area of the tumor cut surface was gelationous. Microscopcally, the tumor was composed of variably sized cystic spaces lined by mucus-rich tumor cells with single columnar, stratified appearance and papillary formation. The degree of cytologic atypia varied from region to region. The tumor cells were positive for CK7, GATA3, negative for CK20, ER, PR and HER2. Most peripheral myoepithelial cells were negative for P63 and SMMHC.
CONCLUSIONS
MCA is a rare primary breast cancer and strikingly similar to ovarian, pancreatic and gastrointestinal counterparts. The diagnosis cannot be made until the metastatic lesion is ruled out. On the other hand, the biologic behavior of MCA is reportedly favorable despite a high proliferation index and triple negative biomarker status. Therefore, the role of adjuvant chemotherapy or radiation is questionable.
PubMed: 33165376
DOI: No ID Found -
The Oncologist Feb 2009During the last decade small lesions of the pancreas have been increasingly recognized in clinical practice. Among these lesions, mucin-producing cystic neoplasms... (Review)
Review
During the last decade small lesions of the pancreas have been increasingly recognized in clinical practice. Among these lesions, mucin-producing cystic neoplasms represent a recently described and unique entity among pancreatic tumors. In 1996, the World Health Organization distinguished two different types of mucinous cystic tumors: intraductal papillary mucinous neoplasms (IPMNs) of the pancreas, which are characterized by mucin production, cystic dilation of the pancreatic ducts, and intrapapillary growth, and mucinous cystic neoplasms (MCNs), which are defined by ovarian-like stroma and in most cases do not communicate with pancreatic ducts. Further, IPMNs can be subdivided into main-duct type, mixed-type, and branch-duct type tumors. Older data did not distinguish among different subsets of cystic neoplasms of the pancreas, and consequently many databases were inconsistent. Histopathologically, both IPMNs and MCNs demonstrate a wide spectrum of cellular atypia ranging from mild mucinous hyperplasia to invasive adenocarcinoma. Because mucinous cystic neoplasms of the pancreas show significant differences in clinical behavior from patient to patient, knowledge of the clinicopathologic characteristics and natural history of specific subtypes of IPMNs and MCNs has become crucial for physicians working in the field of gastroenterology. The present work offers an overview of current and generally accepted clinical guidelines for the diagnosis and treatment of IPMNs and MCNs.
Topics: Carcinoma, Pancreatic Ductal; Cystadenocarcinoma, Mucinous; Humans; Mucins; Pancreatic Neoplasms
PubMed: 19211618
DOI: 10.1634/theoncologist.2008-0200 -
Cancer Science May 2012Uterine papillary serous carcinoma (UPSC) is a rare and aggressive variant of endometrial carcinoma. Little is known about the pathological and biological features of...
Uterine papillary serous carcinoma (UPSC) is a rare and aggressive variant of endometrial carcinoma. Little is known about the pathological and biological features of this tumor. Human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) expression have an important role in tumor behavior and clinical outcome, but their relevance in UPSC is not clear. In the present study, the immunohistochemical expression of HER2 and HR was assessed in 27 patients with Stage I disease, 13 with Stage II disease, 25 with Stage III disease, and 6 with Stage IV disease. Correlations between HER2 and HR expression and the clinicopathological parameters of UPSC were evaluated using Cox's univariate and multivariate analyses. For all patients, the 5-year recurrence-free survival (RFS) and overall survival (OS) rates were 51% and 66%, respectively; in patients with Stage I, II, III and IV disease, the RFS and OS were 67%/81%, 59%/77%, 43%/54% and 0%/0%, respectively. Of all 71 patients, 14% (10/71) were positive for HER2 and 52% (37/71) were positive for HR. Overexpression of HER2 was correlated with lower OS (P = 0.01), whereas HR overexpression was correlated with higher OS (P = 0.008). In multivariate models, HER2, HR, and histologic subtype were identified as independent prognostic indicators for RFS (P = 0.022, P = 0.018, and P = 0.01, respectively), but HR was the only independent factor associated with OS (P = 0.044). Thus, HER2 and HR are prognostic variables in UPSC, with HR an independent prognostic factor for OS.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Uterine Neoplasms
PubMed: 22329832
DOI: 10.1111/j.1349-7006.2012.02240.x -
European Review For Medical and... Apr 2019To investigate the potential effect of microRNA-182-5p (miR-182-5p) on the development of ovarian cancer (OC) and the relevant mechanism.
OBJECTIVE
To investigate the potential effect of microRNA-182-5p (miR-182-5p) on the development of ovarian cancer (OC) and the relevant mechanism.
PATIENTS AND METHODS
The expression levels of miR-182-5p in OC tissues and paracancerous normal tissues were detected. The miR-182-5p expression in OC cells and ovarian epithelial cells was also determined. Through online prediction (TargetScan, miRDB), the potential target of miR-182-5p was screened and further confirmed by the Luciferase reporter gene assay. The effects of the miR-182-5p on human ovarian serous papillary cystadenocarcinoma cell line (SKOV3) cells were determined by in vitro experiments.
RESULTS
The low expression of miR-182-5p in OC was confirmed by quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) assay. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) was identified as a direct target of miR-182-5p. Subsequent experiments showed that the BNIP3 knockdown resulting from the up-regulation of miR-182-5p inhibited cell proliferation, clone formation and migration ability of OC cells.
CONCLUSIONS
Our research showed the inhibitory function of miR-182-5p in OC by targeting BNIP3, thus providing an experimental basis for the treatment of OC.
PubMed: 31081079
DOI: 10.26355/eurrev_201904_17688 -
The Oncologist 2010Pancreatic intraductal papillary mucinous neoplasms (IPMNs) rank among the most common cystic tumors of the pancreas. For a long time they were misdiagnosed as mucinous... (Review)
Review
Pancreatic intraductal papillary mucinous neoplasms (IPMNs) rank among the most common cystic tumors of the pancreas. For a long time they were misdiagnosed as mucinous cystadenocarcinoma, ductal adenocarcinoma in situ, or chronic pancreatitis. Only in recent years have IPMNs been fully recognized as clinical and pathological entities, although their origin and molecular pathogenesis remain poorly understood. IPMNs are precursors of invasive carcinomas. When resected in a preinvasive state patient prognosis is excellent, and even when they are already invasive, patient prognosis is more favorable than with ductal adenocarcinomas. Subdivision into macroscopic and microscopic subtypes facilitates further patient risk stratification and directly impacts treatment. There are main duct and branch duct IPMNs, with the main duct type including the intestinal, pancreatobiliary, and oncocytic types and the branch duct type solely harboring the gastric type. Whereas main duct IPMNs have a high risk for malignant progression, demanding their resection, branch duct IPMNs have a much lower risk for harboring malignancy. Patients with small branch duct/gastric-type IPMNs (<2 cm) without symptoms or mural nodules can be managed by periodic surveillance.
Topics: Adenocarcinoma, Mucinous; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Humans; Pancreatic Neoplasms; Prognosis
PubMed: 21147870
DOI: 10.1634/theoncologist.2010-0151 -
Indian Journal of Cancer 2021The primary retroperitoneal serous adenocarcinoma (PRSAC) is a rare malignant tumor of the retroperitoneum. It shares the same pathological and biological behavior with... (Review)
Review
The primary retroperitoneal serous adenocarcinoma (PRSAC) is a rare malignant tumor of the retroperitoneum. It shares the same pathological and biological behavior with ovarian serous carcinoma. Most of the cases develop as peritoneal adenocarcinoma and rarely occur in the retroperitoneum. It is reported as serous surface papillary carcinoma of the peritoneum and extraovarian peritoneal serous papillary carcinoma. We present a case of PRSAC in a 60-year-old woman. Only 11 cases of PRSAC have been reported from 1983 to 2019. Histopathological features with immunohistochemical expressions are important to diagnose PRSAC. The outcome and survival mainly depend on the possibility of surgical resection. Molecular genetics of PRSAC should also be studied in relation with its ovarian counterpart.
Topics: Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Prognosis; Retroperitoneal Neoplasms
PubMed: 33402586
DOI: 10.4103/ijc.IJC_528_19 -
The Oncologist 2011The study by Uzan and colleagues published in this issue of on the prognosis of patients with serous borderline tumors of the ovary with a micropapillary pattern is...
The study by Uzan and colleagues published in this issue of on the prognosis of patients with serous borderline tumors of the ovary with a micropapillary pattern is reviewed.
Topics: Cystadenocarcinoma, Papillary; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Prognosis; Risk Assessment; Survival Rate
PubMed: 21273513
DOI: 10.1634/theoncologist.2010-0410 -
Histopathologic features and frequency of gall bladder lesions in consecutive 540 cholecystectomies.International Journal of Clinical and... 2013The frequency of gall bladder lesions in cholecystectomies is not clear. The purpose of the present study is to report the morphologies and frequency of gall bladder...
The frequency of gall bladder lesions in cholecystectomies is not clear. The purpose of the present study is to report the morphologies and frequency of gall bladder diseases and lesions of 540 cholecystectomies in the last 10 years in our pathology laboratory. The age of patients ranged from 18 years to 93 years with a mean of 64.75 ±14.43 years. Male to female ratio was 213:327. Of these, 518 cases (96%) had gall stones. Eight (1.5%) were acute cholecystitis, 508 (94.1%) were chronic cholecystitis, 12 (2.2%) were adenocarcinomas, 1 (0.2%) was cystadenocarcinoma, and 11 (2.0%) were normal gall bladders. The frequency of histological lesions were as follows: acute gangrenous inflammation (8 cases, 1.5%), Rokitansky-Aschoff sinuses (RAS) (351 cases, 65%), microliths or inspissated bile in RAS (108 cases, 20%), adenomyomatous changes (16 cases, 3.0 %), focal abscess formations (12 cases, 2.2%), focal xanthogranulomatous changes (15 cases, 2.8%), mucosal ulcers (61 cases, 11.3%), cholesterosis (62 cases, 11%), cholesterol polyp (32 cases, 6%), pyloric gland metaplasia (292 cases, 54%), adenoma (7 cases, 1.3%), xanthogranulomatous cholecystitis (5 cases, 1%), invasive adenocarcinoma (12 cases, 2.2%), and cystadenocarcinoma (1 cases, 0.2%). In adenomyomatous changes, the epithelial proliferation was florid in a few cases, and no perineural invasions were seen. In pyloric gland metaplasia, no perineural invasions were recognized. All the 7 cases of adenoma were of intestinal type. In the 12 adenocarcinoma cases, one case arose in RAS without mucosal involvement, and 9 were tubular adenocarcinomas and 3 were papillary adenocarcinomas and 1 was mucinous adenocarcinoma. In the present series, there were no cases of heterotipc tissue, intestinal metaplasia, intraepithelial neoplasm, and other malignancies. These data may provide basic knowledge of the gall bladder pathologies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholecystectomy; Female; Gallbladder Diseases; Humans; Incidence; Male; Middle Aged; Young Adult
PubMed: 23236547
DOI: No ID Found -
Diagnostic Pathology Feb 2013Low-grade cribriform cystadenocarcinoma (LGCCC) is a recently described rare tumor of salivary gland which exhibits clinically indolent behavior. This tumor... (Review)
Review
UNLABELLED
Low-grade cribriform cystadenocarcinoma (LGCCC) is a recently described rare tumor of salivary gland which exhibits clinically indolent behavior. This tumor predominantly consists of intraductal components and frequently exhibits papillary-cystic or cribriform proliferation pattern. Considering the histological features of LGCCC, it should be distinguished with papillocystic variant of acinic cell carcinoma, conventional salivary duct carcinoma, cystadenocarcinoma, polymorphous low-grade adenocarcinoma, carcinoma ex pleomorphic adenoma and mammary analogue secretory carcinoma. Herein, we presented two cases of LGCCC. One arose in the left parotid region in a 48-year-old male, and the other one arose in the right parotid gland in a 59-year-old female. For both cases, immunohistochemically, the luminal tumor cells showed diffuse expression of CK and S100; p63 and smooth muscle actin displayed a continuous rim of myoepithelial cells around all tumor islets; no myoepithelial cells were admixed with the luminal cells. Both patients were alive with no tumor recurrence or metastasis at follow-up.
VIRTUAL SLIDES
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2593621568999135.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cystadenocarcinoma; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Grading; Parotid Neoplasms; Predictive Value of Tests
PubMed: 23419146
DOI: 10.1186/1746-1596-8-28